SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Orbifloxacin Liquid Formulation

Version: 2.8
Revision Date: 2019/09/13
SDS Number: 785427-00010
Date of last issue: 2019/04/24
Date of first issue: 2016/06/28

1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Orbifloxacin Liquid Formulation

Manufacturer or supplier’s details
Company: MSD
Address: No. 485 Jing Tai Road
Pu Tuo District - Shanghai - China 200331
Telephone: 908-740-4000
Emergency telephone number: 86-571-87268110
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product

2. HAZARDS IDENTIFICATION

Emergency Overview
Appearance: suspension
Colour: light brown
Odour: odourless

Suspected of damaging the unborn child. May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

GHS Classification
Reproductive toxicity: Category 2
Specific target organ toxicity - repeated exposure (Oral): Category 2 (Eye)

GHS label elements
Hazard pictograms:

Signal word: Warning

Hazard statements: H361d Suspected of damaging the unborn child. H373 May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

Precautionary statements:
Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read
and understood.
P260 Do not breathe mist or vapours.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Physical and chemical hazards
Not classified based on available information.

Health hazards
Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed.

Environmental hazards
Not classified based on available information.

Other hazards which do not result in classification
None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Mixture</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical name</td>
<td>CAS-No.</td>
</tr>
<tr>
<td>Orbifloxacin</td>
<td>113617-63-3</td>
</tr>
<tr>
<td>Silicon dioxide</td>
<td>7631-86-9</td>
</tr>
<tr>
<td>Lactic acid</td>
<td>50-21-5</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>1310-73-2</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice
In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled
If inhaled, remove to fresh air. Get medical attention.

In case of skin contact
In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse.
Orbifloxacin Liquid Formulation

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Metal oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions: Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 7. HANDLING AND STORAGE

**Handling**

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling:
- Avoid inhalation of vapour or mist.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact: Oxidizing agents

**Storage**

Conditions for safe storage: Keep in properly labelled containers.
- Store locked up.
- Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types:
- Strong oxidizing agents

Packaging material: Unsuitable material: None known.

### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orbifloxacin</td>
<td>113617-63-3</td>
<td>TWA</td>
<td>0.2 mg/m3 (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Silicon dioxide</td>
<td>7631-86-9</td>
<td>PC-TWA (Total dust)</td>
<td>5 mg/m3</td>
<td>GBZ 2.1-2007</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>1310-73-2</td>
<td>MAC</td>
<td>2 mg/m3</td>
<td>GBZ 2.1-2007</td>
</tr>
</tbody>
</table>

#### Engineering measures:

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Combined particulates and organic vapour type

Eye/face protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat.

Hand protection: Chemical-resistant gloves

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: suspension

Colour: light brown

Odour: odourless

Odour Threshold: No data available

pH: No data available

Melting point/freezing point: No data available

Initial boiling point and boiling range: No data available

Flash point: No data available

Evaporation rate: No data available

Flammability (solid, gas): Not applicable
10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Can react with strong oxidizing agents.
Conditions to avoid: None known.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes: Inhalation, Skin contact
Ingestion
Eye contact

**Acute toxicity**
Not classified based on available information.

**Product:**
Acute oral toxicity: Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

**Components:**

**Orbifloxacin:**
Acute oral toxicity: LD50 (Rat): > 3,000 mg/kg
Remarks: No mortality observed at this dose.
LD50 (Mouse): > 2,000 mg/kg
Remarks: No mortality observed at this dose.
LD50 (Dog): > 600 mg/kg
Symptoms: Vomiting
Remarks: No mortality observed at this dose.

Acute inhalation toxicity: Remarks: No data available

Acute dermal toxicity: Remarks: No data available

Acute toxicity (other routes of administration): LD50 (Rat): > 200 mg/kg
Application Route: Intramuscular
LD50 (Mouse): 500 mg/kg
Application Route: Intramuscular
LD50 (Rat): 233 mg/kg
Application Route: Intravenous
LD50 (Mouse): 250 mg/kg
Application Route: Intravenous

**Silicon dioxide:**
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 401

Acute inhalation toxicity: LC50 (Rat): > 2.08 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity: LD50 (Rabbit): > 5,000 mg/kg

**Lactic acid:**
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
Remarks: Based on data from similar materials

Acute inhalation toxicity: LC50 (Rat): > 5 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Remarks: Based on data from similar materials

Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity
Remarks: Based on data from similar materials

Sodium hydroxide:
Acute inhalation toxicity: Assessment: Corrosive to the respiratory tract.

Skin corrosion/irritation
Not classified based on available information.

Product:
Species: Rabbit
Result: No skin irritation

Components:
Orbifloxacin:
Species: Rabbit
Method: Draize Test
Result: No skin irritation

Silicon dioxide:
Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation

Lactic acid:
Species: Rabbit
Result: Skin irritation
Remarks: Based on data from similar materials

Sodium hydroxide:
Result: Corrosive after 3 minutes or less of exposure

Serious eye damage/eye irritation
Not classified based on available information.

Product:
Species: Rabbit
Orbifloxacin Liquid Formulation

Result : Mild eye irritation

Components:

Orbifloxacin:
Species : Rabbit
Result : Mild eye irritation
Method : Draize Test

Silicon dioxide:
Species : Rabbit
Result : No eye irritation
Method : OECD Test Guideline 405

Lactic acid:
Species : Chicken eye
Result : Irreversible effects on the eye
Remarks : Based on data from similar materials

Sodium hydroxide:
Result : Irreversible effects on the eye
Remarks : Based on skin corrosivity.

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Product:
Test Type : Magnusson-Kligman-Test
Exposure routes : Dermal
Species : Guinea pig
Result : Not a skin sensitizer.

Components:

Orbifloxacin:
Test Type : Maximisation Test
Exposure routes : Dermal
Species : Guinea pig
Result : Not a skin sensitizer.

Lactic acid:
Test Type : Buehler Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative
Sodium hydroxide:

Test Type: Human repeat insult patch test (HRIPT)
Exposure routes: Skin contact
Result: negative

Germ cell mutagenicity
Not classified based on available information.

Components:

Orbifloxacin:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: equivocal

Test Type: Mouse Lymphoma
Result: positive

Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: positive

Genotoxicity in vivo:
Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Intraperitoneal injection
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment: Weight of evidence does not support classification as a germ cell mutagen.

Silicon dioxide:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Genotoxicity in vivo: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Lactic acid:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Orbifloxacin Liquid Formulation

Method: OECD Test Guideline 471
Result: negative
Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity
Not classified based on available information.

Components:

Orbifloxacin:
Species: Rat
Application Route: Oral
Exposure time: 2 Years
NOAEL: 200 mg/kg body weight
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 2 Years
NOAEL: 200 mg/kg body weight
Result: negative

Silicon dioxide:
Species: Rat
Application Route: Ingestion
Exposure time: 103 weeks
Result: negative

Lactic acid:
Species: Rat
Application Route: Ingestion
Exposure time: 2 Years
Result: negative
Remarks: Based on data from similar materials

Reproductive toxicity
Suspected of damaging the unborn child.

Components:

Orbifloxacin:
Effects on fertility: Test Type: Two-generation reproduction toxicity study
Orbifloxacin Liquid Formulation

<table>
<thead>
<tr>
<th>Species: Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route: Oral</td>
</tr>
<tr>
<td>General Toxicity - Parent: NOAEL: 50 mg/kg body weight</td>
</tr>
<tr>
<td>Early Embryonic Development: NOAEL: 50 mg/kg body weight</td>
</tr>
<tr>
<td>Result: No adverse effects</td>
</tr>
</tbody>
</table>

**Effects on foetal development**

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Oral</td>
</tr>
<tr>
<td>Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight</td>
</tr>
<tr>
<td>Result: No teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rabbit</td>
</tr>
<tr>
<td>Application Route: Oral</td>
</tr>
<tr>
<td>General Toxicity Maternal: NOAEL: 20 mg/kg body weight</td>
</tr>
<tr>
<td>Embryo-foetal toxicity: NOAEL: 60 mg/kg body weight</td>
</tr>
<tr>
<td>Result: No effects on early embryonic development, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Dog</td>
</tr>
<tr>
<td>Application Route: Oral</td>
</tr>
<tr>
<td>Developmental Toxicity: LOAEL: 2.5 mg/kg body weight</td>
</tr>
<tr>
<td>Result: Effects on postnatal development, Skeletal malformations</td>
</tr>
</tbody>
</table>

**Reproductive toxicity - Assessment**

| Some evidence of adverse effects on development, based on animal experiments. |

**Silicon dioxide:**

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Ingestion</td>
</tr>
<tr>
<td>Result: negative</td>
</tr>
</tbody>
</table>

**Lactic acid:**

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Mouse</td>
</tr>
<tr>
<td>Application Route: Ingestion</td>
</tr>
<tr>
<td>Result: negative</td>
</tr>
</tbody>
</table>

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.
Orbifloxacin Liquid Formulation

Target Organs: Eye
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Product:
Species: Dog
NOAEL: 22.5 mg/kg
LOAEL: 37.5 mg/kg
Application Route: Oral
Exposure time: 30 Days
Symptoms: Gastrointestinal disturbance

Species: Dog
NOAEL: 75 mg/kg
LOAEL: 37.5 mg/kg
Application Route: Oral
Exposure time: 10 Days
Symptoms: Salivation, Gastrointestinal disturbance, Vomiting

Species: Cat
NOAEL: 45 mg/kg
LOAEL: 75 mg/kg
Application Route: Oral
Exposure time: 30 Days
Target Organs: Eye
Symptoms: Salivation, Lachrymation, Gastrointestinal disturbance, Liver disorders

Components:

Orbifloxacin:
Species: Rat
NOAEL: 20 mg/kg
LOAEL: 80 mg/kg
Application Route: Oral
Exposure time: 3 Months
Target Organs: Testis, Liver, Kidney, spleen

Species: Mouse
NOAEL: 80 mg/kg
LOAEL: 250 mg/kg
Application Route: Oral
Exposure time: 3 Months

Species: Juvenile dog
NOAEL: 50 mg/kg
LOAEL: 250 mg/kg
Application Route: Oral
Exposure time: 14 Days
Target Organs: Heart, Bone
Symptoms: Gastrointestinal disturbance
Remarks: mortality observed
Species: Juvenile dog  
NOAEL: 2 mg/kg  
LOAEL: 3 mg/kg  
Application Route: Oral  
Exposure time: 90 Days  
Target Organs: Bone  
Remarks: No significant adverse effects were reported

Species: Dog  
NOAEL: 37.5 mg/kg  
Application Route: Oral  
Exposure time: 30 Days

Species: Cat  
NOAEL: 7.5 mg/kg  
LOAEL: 22.5 mg/kg  
Application Route: Oral  
Exposure time: 1 Months  
Symptoms: Gastrointestinal disturbance

Silicon dioxide:  
Species: Rat  
NOAEL: 1.3 mg/m³  
Application Route: Inhalation (dust/mist/fume)  
Exposure time: 13 Weeks

Lactic acid:  
Species: Rat  
NOAEL: > 100 mg/kg  
Application Route: Ingestion  
Exposure time: 13 Weeks  
Remarks: Based on data from similar materials

Species: Rat  
LOAEL: 886 mg/kg  
Application Route: Skin contact  
Exposure time: 13 Weeks

Aspiration toxicity  
Not classified based on available information.

Experience with human exposure

Components:

Orbifloxacin:  
Ingestion: Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash  
Remarks: May cause photosensitisation.
12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Silicon dioxide:
Toxicity to fish : LC50 (Danio rerio (zebra fish)) : > 10,000 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)) : > 1,000 mg/l
Exposure time: 24 h
Method: OECD Test Guideline 202

Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants : EC50 (Desmodesmus subspicatus (green algae)) : > 10,000 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

NOEC (Desmodesmus subspicatus (green algae)) : 10,000 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Lactic acid:
Toxicity to fish : LC50 (Danio rerio (zebra fish)) : > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)) : > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)) : > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

NOEC (Pseudokirchneriella subcapitata (green algae)) : > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC50: > 10 - 100 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209
Orbifloxacin Liquid Formulation

Persistence and degradability

**Components:**

Lactic acid:
Biodegradability : Result: Not readily biodegradable.
Remarks: Based on data from similar materials

Bioaccumulative potential

**Components:**

Lactic acid:
Partition coefficient: n-octanol/water : log Pow: -0.62

Mobility in soil
No data available

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

GB 6944/12268
Not regulated as a dangerous good

Special precautions for user
Not applicable
15. REGULATORY INFORMATION

National regulatory information
Law on the Prevention and Control of Occupational Diseases

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

16. OTHER INFORMATION

Further information

Date format: yyyy/mm/dd

Full text of other abbreviations
ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / C : Ceiling limit
GBZ 2.1-2007 / PC-TWA : Permissible concentration - time weighted average
GBZ 2.1-2007 / MAC : Maximum allowable concentration

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Develop-
Orbifloxacin Liquid Formulation

Version 2.8
Revision Date: 2019/09/13
SDS Number: 785427-00010
Date of last issue: 2019/04/24
Date of first issue: 2016/06/28

Disclaimer
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN